Background: Warfarin is used to prevent stroke in patients with atrial fibrillation (AF).
| INTRODUCTION
Warfarin is an oral anticoagulant used for both the prevention and treatment of thromboembolism, including stroke as a result of atrial fibrillation (AF). 1 Patient variability in warfarin response and a narrow therapeutic index necessitates monitoring of the international normalised ratio (INR) to guide therapy. 2 Tight control of INR between 2.0 and 3.0 is the strategy used to ensure optimal benefit of warfarin while minimising risk. 3 Time in therapeutic range (TTR) is a routinely used measure of warfarin control in clinical settings, with patients obtaining lower TTR more likely to experience negative outcomes such as haemorrhage or stroke. 4 A minimum threshold TTR of 65% is recommended, 5 24 However, to the best of our knowledge, there are no Australian data comparing warfarin management by the GP and dedicated warfarin programmes.
Therefore, the aim of this study was to determine the level of warfarin control as measured by TTR in patients managed by their GP and when managed by a pathology laboratory offering a warfarin management programme in Queensland, Australia. 
| METHODS

What's new
• This is the first study comparing warfarin management options in Australia. This study found a high level of warfarin control when managed by general practitioners (69% TTR) and a warfarin care programme (82% TTR).
Both management options achieved warfarin control
above TTR targets of 65%, but the increased control by the dedicated warfarin programme can further improve outcomes and optimise therapy for patients placed on warfarin.
| RESULTS
Of Of the 200 patients included in the study, there were 104 (52%) males and 96 (48%) females (Table 1 ). The mean age of the patients at the time of enrolment at WCP was 78.9 ± 7.5 years.
The overall mean TTR was 68.5 ± 16.2% when managed by the GP and 81.5 ± 9.1% when managed at WCP, which was significantly different (P<.0001) ( 
| DISCUSSION
Warfarin is an effective therapy for the prevention of stroke in patients with AF, but differences in TTR can affect outcomes. 6 Anticoagulant clinics have been suggested to improve outcomes and optimise TTR, 25 however reported TTR increases have varied. by the GP and dedicated anticoagulant clinics. Therefore, the aim of this study was to determine the level of warfarin control in AF patients when managed by their GP and by a pathology practice offering a warfarin management programme in Queensland, Australia. This study found significant differences in mean TTR between GP and WCP management for the overall time period (69% and 82%, respectively), and for the six-month period (68% and 80%, respectively) either side of enrolment in the warfarin management programme. Significant differences were also found at these time periods between GP and WCP management in the percentage of tests in range, total number of tests, frequency of testing and interval to next INR test.
The Australian TTR data from the comparative trials of warfarin and the NOACs was 73%-76%. [7] [8] [9] In our study, the GP TTR of 69% was 4-7% below the mean Australian TTR, and the WCP TTR of 82% was 9%-12% above these values. In comparison, van Walraven et al 15 and improved patient education. 31 Because of the retrospective nature of our study and access only to INR results prior to enrolment at the clinic, we were unable to measure outcomes in terms of adverse events and influence of interacting medications. However, TTR has been shown to be a good surrogate marker of outcomes with warfarin therapy, [36] [37] [38] and enrolment in the dedicated warfarin clinic was shown to improve TTR even after only a six-month period. This is likely to translate into improved outcomes from warfarin therapy but further investigation is required to confirm this improvement in terms of clinical efficacy and safety. Further investigation should also include other Australian States and Territories to determine if warfarin management programmes could improve warfarin control on a nationwide level and ensure optimal outcomes for patients on warfarin.
In conclusion, this study found a high level of warfarin control in Australia with a TTR of 69% when managed by the GP and 82%
when managed at WCP. The TTR for both management approaches is above recommended targets of 65%, suggesting good management by Australian GPs but superior control by the dedicated WCP. These findings suggest that dedicated warfarin management programmes can improve warfarin control for Australian patients and are an important approach to optimise TTR and warfarin therapy for patients.
